Cellectis (NASDAQ:CLLS) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Cellectis (NASDAQ:CLLSGet Rating) from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. They currently have $4.00 price target on the biotechnology company’s stock.

According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “

CLLS has been the subject of a number of other research reports. StockNews.com raised shares of Cellectis from a sell rating to a hold rating in a research note on Wednesday. Barclays lowered their price target on shares of Cellectis from $9.00 to $7.00 in a report on Friday, May 13th. Finally, Robert W. Baird upgraded shares of Cellectis from a neutral rating to an outperform rating and set a $10.00 price target for the company in a report on Wednesday. They noted that the move was a valuation call. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Buy and a consensus price target of $17.14.

CLLS stock opened at $3.78 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.73 and a quick ratio of 3.73. Cellectis has a one year low of $2.85 and a one year high of $16.67. The stock has a market cap of $171.95 million, a PE ratio of -1.28 and a beta of 2.24. The firm has a 50 day simple moving average of $4.00 and a two-hundred day simple moving average of $6.14.

Cellectis (NASDAQ:CLLSGet Rating) last released its quarterly earnings results on Thursday, March 3rd. The biotechnology company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.50. Cellectis had a negative net margin of 312.64% and a negative return on equity of 53.48%. The business had revenue of $13.66 million during the quarter, compared to analysts’ expectations of $12.30 million. During the same quarter in the previous year, the company earned ($0.95) EPS. On average, research analysts expect that Cellectis will post -2.19 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. US Bancorp DE grew its position in Cellectis by 94.0% during the 3rd quarter. US Bancorp DE now owns 2,332 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,130 shares during the last quarter. Signaturefd LLC grew its position in Cellectis by 1,066.0% during the 4th quarter. Signaturefd LLC now owns 3,801 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 3,475 shares during the last quarter. Advisor Group Holdings Inc. grew its position in Cellectis by 73.9% during the 4th quarter. Advisor Group Holdings Inc. now owns 4,950 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 2,103 shares during the last quarter. Deutsche Bank AG purchased a new stake in shares of Cellectis during the 3rd quarter valued at about $42,000. Finally, Marshall Wace LLP purchased a new stake in shares of Cellectis during the 4th quarter valued at about $44,000. Institutional investors own 40.55% of the company’s stock.

Cellectis Company Profile (Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Read More

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.